Given our recent development of multiple anti-FABP4 antibodies, which showed significant efficacy in reducing mammary tumor growth and metastasis in animal models [29], FABP4 and FABP5 represent promising therapeutic targets, and blocking their activity may offer novel strategies for breast cancer treatment. Here, FABP5 is linked to breast carcinoma.